Sarah R Martha1, Kuan-Fu Chen2, Yvonne Lin2, Hilaire J Thompson3. 1. Omics and Symptom Science Training Program in Biobehavioral Nursing and Health Informatics Department, School of Nursing, 7284University of Washington, Seattle, WA, USA. 2. Department of Pharmaceutics, School of Pharmacy, 7284University of Washington, Seattle WA, USA. 3. Biobehavioral Nursing and Health Informatics Department, School of Nursing and Harborview Injury Prevention and Research Center, 7284University of Washington, Seattle, WA, USA.
Abstract
OBJECTIVE: To compare differences using a metabolomics approach in older adults (≥55) with mild traumatic brain injury (mTBI) to control adults and to identify a signature profile related to functional outcome 3-6 months post-injury. METHODS: We performed metabolomics analysis using LC-MS of untargeted aqueous metabolites on plasma samples taken from a parent prospective cohort study. Older adults with mTBI (n = 14) were purposively sampled to include participants with worsening (decrease in GOS-E of at least 1 level) and improved (increase in GOS-E of at least 1 level) outcomes from 3 to 6 months. The data were analyzed using PLS-DA with VIP scores, Random Forest, and spline fit between the different groups as a function of time for exposure on outcome. RESULTS: Separation of comparisons were seen at 24 hours (negative ionization) and 6 months (positive ionization), revealing two metabolites of interest, phosphatidylcholine and phosphatidylethanolamine. Phosphatidylcholine levels were higher in those with mTBI compared to controls (p < 0.05), while lower concentration of phosphatidylethanolamine was seen in those with mTBI compared to controls (p < 0.05). Phosphatidylinositol-3,4,5-trisphosphate was significant in those with mTBI compared to controls (n = 10) based on improved (n = 6) versus worsened (n = 8) outcomes from 3 to 6 months. CONCLUSION: We identified plasma metabolites related to phospholipid metabolism in older adults following mTBI and associated with long-term functional outcome. These findings may underly pathological mechanisms of outcome differences in older adults who experience mTBI.
OBJECTIVE: To compare differences using a metabolomics approach in older adults (≥55) with mild traumatic brain injury (mTBI) to control adults and to identify a signature profile related to functional outcome 3-6 months post-injury. METHODS: We performed metabolomics analysis using LC-MS of untargeted aqueous metabolites on plasma samples taken from a parent prospective cohort study. Older adults with mTBI (n = 14) were purposively sampled to include participants with worsening (decrease in GOS-E of at least 1 level) and improved (increase in GOS-E of at least 1 level) outcomes from 3 to 6 months. The data were analyzed using PLS-DA with VIP scores, Random Forest, and spline fit between the different groups as a function of time for exposure on outcome. RESULTS: Separation of comparisons were seen at 24 hours (negative ionization) and 6 months (positive ionization), revealing two metabolites of interest, phosphatidylcholine and phosphatidylethanolamine. Phosphatidylcholine levels were higher in those with mTBI compared to controls (p < 0.05), while lower concentration of phosphatidylethanolamine was seen in those with mTBI compared to controls (p < 0.05). Phosphatidylinositol-3,4,5-trisphosphate was significant in those with mTBI compared to controls (n = 10) based on improved (n = 6) versus worsened (n = 8) outcomes from 3 to 6 months. CONCLUSION: We identified plasma metabolites related to phospholipid metabolism in older adults following mTBI and associated with long-term functional outcome. These findings may underly pathological mechanisms of outcome differences in older adults who experience mTBI.
Entities:
Keywords:
aged; head injury; metabolomics; phospholipids
Authors: Cameron B Jeter; Georgene W Hergenroeder; Norman H Ward; Anthony N Moore; Pramod K Dash Journal: J Neurotrauma Date: 2011-11-21 Impact factor: 5.269
Authors: David S Wishart; Dan Tzur; Craig Knox; Roman Eisner; An Chi Guo; Nelson Young; Dean Cheng; Kevin Jewell; David Arndt; Summit Sawhney; Chris Fung; Lisa Nikolai; Mike Lewis; Marie-Aude Coutouly; Ian Forsythe; Peter Tang; Savita Shrivastava; Kevin Jeroncic; Paul Stothard; Godwin Amegbey; David Block; David D Hau; James Wagner; Jessica Miniaci; Melisa Clements; Mulu Gebremedhin; Natalie Guo; Ying Zhang; Gavin E Duggan; Glen D Macinnis; Alim M Weljie; Reza Dowlatabadi; Fiona Bamforth; Derrick Clive; Russ Greiner; Liang Li; Tom Marrie; Brian D Sykes; Hans J Vogel; Lori Querengesser Journal: Nucleic Acids Res Date: 2007-01 Impact factor: 16.971
Authors: Pramod K Dash; Georgene W Hergenroeder; Cameron B Jeter; H Alex Choi; Nobuhide Kobori; Anthony N Moore Journal: Front Syst Neurosci Date: 2016-04-29
Authors: Matej Orešič; Jussi P Posti; Maja H Kamstrup-Nielsen; Riikka S K Takala; Hester F Lingsma; Ismo Mattila; Sirkku Jäntti; Ari J Katila; Keri L H Carpenter; Henna Ala-Seppälä; Anna Kyllönen; Henna-Riikka Maanpää; Jussi Tallus; Jonathan P Coles; Iiro Heino; Janek Frantzén; Peter J Hutchinson; David K Menon; Olli Tenovuo; Tuulia Hyötyläinen Journal: EBioMedicine Date: 2016-07-15 Impact factor: 8.143